Background
Janssen holds a patent for specific dosing regimens of paliperidone palmitate, a long-acting injectable antipsychotic used to treat schizophrenia and related disorders. The patent discloses a two-dose initiation phase followed by monthly maintenance doses, with different dose levels for patients with and without impaired kidney function. The dosing regimen is implemented through injections into either the deltoid or gluteal muscle on a set schedule.
Pharmascience, a generic drug manufacturer, sought approval to market a generic version of the same drug. When Pharmascience attempted to obtain regulatory approval, it challenged Janssen’s patent in federal court, arguing that the patent claims an unpatentable method of medical treatment—a category of subject matter excluded from patent protection under Canadian law. The Federal Court and Federal Court of Appeal both rejected this challenge and upheld the patent’s validity.
Pharmascience appealed to the Supreme Court of Canada, raising the question of whether dosing regimens for pharmaceutical products constitute unpatentable methods of medical treatment.
The Court’s Holding
By a 6-3 majority (with two justices concurring on the result but disagreeing on reasoning), the Supreme Court dismissed Pharmascience’s appeal and upheld the patent. The majority, written by Justice Jamal, affirmed the longstanding Canadian principle that methods of medical treatment are not patentable subject matter because they constitute professional skills that lie outside the scope of patentable inventions. However, the majority concluded that Janssen’s patent does not impermissibly claim a method of medical treatment.
The majority established a test for determining whether a claimed invention constitutes an unpatentable method of medical treatment: a patent violates this prohibition only if it seeks to monopolize professional medical skill and judgment—that is, if it “fences in” an area of medical treatment. The court identified three guiding principles: (1) the focus should be on whether the subject matter itself requires professional judgment, not whether its use does; (2) the more the subject matter requires individualized treatment tailoring, the more likely it is unpatentable; and (3) the more a medical professional would naturally develop it in ordinary practice, the more likely it is unpatentable. The majority stressed these are not bright-line rules but fact-specific considerations.
Applying this test, the majority found Janssen’s patent claims patentable subject matter. The dosing regimen can be applied generally to a broad class of patients without individualized adjustment and does not require ongoing professional judgment in its administration once a physician selects it. The separate dosing levels for patients with renal impairment reflect objective clinical criteria, not subjective medical judgment. Accordingly, the patent does not monopolize professional medical skill and therefore is not barred from patentability on this ground.
Key Takeaways
- Methods of medical treatment remain unpatentable in Canada, but the prohibition applies only to patents that monopolize professional medical skill and judgment.
- Pharmaceutical dosing regimens can constitute patentable subject matter if they can be applied generally without requiring individualized clinical judgment for each patient.
- The patentability analysis for medical inventions must focus on the nature of the claimed subject matter itself, not on whether professional skill and judgment are required to use it.
- A concurring opinion (two justices) argued methods of medical treatment should not be inherently excluded from patentability, suggesting potential future evolution of Canadian patent law in this area.
Why It Matters
This decision provides crucial clarification on a contentious issue in Canadian patent law. For over fifty years, courts have stated that methods of medical treatment are unpatentable, but the precise boundaries of this rule remained uncertain. Generic manufacturers argued that any patent involving medical dosing could be invalidated on this ground. This decision resolves that ambiguity: pharmaceutical patents claiming fixed or generally applicable dosing regimens are patentable if they do not require ongoing individualized professional judgment. This gives pharmaceutical innovators meaningful patent protection for new dosing regimens while preserving physicians’ clinical autonomy.
The decision also reflects a tension within the Court itself. Two justices argued in a concurring opinion that the entire prohibition on patenting medical methods should be reconsidered, suggesting that utility requirements (not categorical exclusion) should filter out unpatentable medical inventions. This signals that the settled law on medical method patents may face future challenges and that the parameters of pharmaceutical patent protection in Canada may continue to evolve.